A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Drug Used to Treat Prostate Cancer May Have Off-Label Use for COVID-19


A Brazilian study on the use of proxalutamide, a new drug indicated for prostate cancer, provided unexpected benefits for hospitalized patients with COVID-19. Results showed that 81% of patients with COVID-19 who received proxalutamide for 2 weeks survived, compared to 36% of those who were given a placebo. The study was composed of 645 patients with COVID-19 who were hospitalized but still breathing independently. At the 4-week mark, only 11% of the group taking proxalutamide had died, compared with 49% of the placebo group. The medication inactivates androgen hormones by hindering their receptors on the surface of cells. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy